FDA/CMS Formal Collaboration Will Include Data Sharing, Parallel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
A draft memorandum of understanding is under review at both agencies, Centers for Medicare & Medicaid Services Chief Medical Officer Sean Tunis, MD, told the BIO annual meeting in San Francisco. The MOU will address parallel review for new technologies, and allow the agencies to share scientific expertise and data.
You may also be interested in...
FDA, CMS To Begin Collaborating On Drug Safety Data Collection In 2005
HHS Medical Innovation Task Force report says CMS will assist FDA in postmarketing drug surveillance. The collaboration also includes parallel reviews by the two agencies to minimize delays between marketing approval and reimbursement.
FDA, CMS To Begin Collaborating On Drug Safety Data Collection In 2005
HHS Medical Innovation Task Force report says CMS will assist FDA in postmarketing drug surveillance. The collaboration also includes parallel reviews by the two agencies to minimize delays between marketing approval and reimbursement.
Agency Will Request More Voluntary Safety Data Disclosure By Sponsors
Controversy involving pediatric antidepressant use has encouraged FDA to accelerate public release of safety review data, Acting Deputy Commissioner for Policy Sachdev says. A planned partnership with CMS will also allow for better post-marketing safety surveillance.